top of page
OUR PIPELINE
Publications & Presentations
Presented at American Academy of Allergy, Asthma & Immunology, Feb 28 - Mar 3, 2025, San Diego, CA
These data demonstrate that a surrogate for solrikitug reduces inflammation in a preclinical model of asthma, with solrikitug showing 10 times more potency than tezepelumab at inhibiting TSLP-induced human dendritic cell activation.
We are actively expanding our immunology and inflammation pipeline, with a laser focus on therapeutics for indications with limited or no available treatments.
bottom of page